Urol

Quick links to important sections

Urol

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urol

Quick Facts

Property Description
Active ingredient Flavoxate hydrochloride
Form Oral tablet
Pharmacological class Urinary Antispasmodic
Origin Synthetic

What Type of Medicine is Urol?

Urol is a prescription medication classified as a Urinary Antispasmodic, containing the active substance Flavoxate. This classification places Urol within the broader category of Urological Agents specifically designed to influence the muscle function of the lower urinary tract. The active substance, Flavoxate hydrochloride, is a complex compound that is synthetic in origin, not derived from natural sources, and is formulated as a single-active ingredient product. This drug is recognized for its action on the genitourinary smooth muscle.


Composition and Dosage Form

The core therapeutic component of Urol is Flavoxate hydrochloride, which is exclusively provided in the form of an oral tablet. This specific dosage form determines the oral route of administration for systemic delivery of the active agent. Each oral tablet comprises the precise amount of Flavoxate hydrochloride, a Flavone Derivative, integrated within a solid pharmaceutical base or excipient matrix, ensuring consistent and controlled release for effective absorption. The efficacy of the compound relies on its direct spasmolytic action.


General Purpose and Benefit

The general purpose of Urol is to provide relief by achieving direct smooth muscle relaxation in the walls of the urinary tract, a mechanism recognized for its efficacy in managing bladder discomfort. By addressing the physical cause of irritation—the excessive muscle activity—Urol helps to reduce unwanted, sudden contractions, or spasm. This action stabilizes the bladder and provides the general benefit of calming the urinary system, easing the core discomfort related to muscle tension and involuntary hyperactivity, such as the persistent feeling of urgency. Other common brands sharing this Flavoxate formulation include Urispas and Genurin, confirming its standard use as an oral antispasmodic.

Regulatory References

  1. Flavoxate: MedlinePlus Drug Information

What side effects are possible with Urol?

Possible Side Effects and Safety Information

The officially documented safety profile of Urol (Flavoxate hydrochloride) is based on regulatory classifications of adverse reactions by frequency and affected physiological system, as published in government sources such as the FDA and European Summary of Product Characteristics (SmPC).

Official Adverse Reactions and System Groupings

Adverse reactions are formally grouped by System-Organ Classes (SOC) and primarily involve the Gastrointestinal, Nervous, and Ophthalmic systems. Gastrointestinal effects include dry mouth (classified as Common in some regions), nausea, vomiting, and dyspepsia (often Uncommon). Nervous system reactions include drowsiness (somnolence), headache, and vertigo. Ophthalmic effects such as visual impairment (e.g., blurred vision) are also documented. Changes in heart rhythm, such as palpitation and tachycardia, are listed under Cardiac disorders.

Serious Safety Concerns and Restrictions

The regulatory labeling includes documentation of rare but clinically significant reactions, such as anaphylactic reaction/shock and changes in blood counts like reversible leukopenia. Use of the medicine is formally restricted (contraindicated) in the presence of certain conditions, including glaucoma (due to the potential for increased ocular tension), myasthenia gravis, obstructive uropathies (urinary retention), and severe gastrointestinal obstructive conditions (e.g., pyloric obstruction).

Population-Specific Safety Notes

The official documentation includes specific safety considerations for certain patient groups. A potential for mental confusion is explicitly noted, particularly for older adults. Furthermore, the safety and effectiveness of Urol have not been established for use in children below 12 years of age. Caution is required for patients with renal impairment, as clearance of the active metabolite is highly dependent on kidney function.

Overdose and Emergency Response

The official regulatory documentation for Urol (Flavoxate hydrochloride) outlines specific clinical manifestations that have been documented to occur following an overdose. These documented signs primarily involve the Central Nervous System (CNS) and include severe drowsiness, severe dizziness, clumsiness or unsteadiness, and formal descriptions of hallucinations. Additional systemic signs listed in official labeling include fever and flushing or redness of the face, along with noted behavioral changes such as unusual excitement, nervousness, or irritability.

The most critical regulatory instruction dictates when to seek immediate medical attention. Emergency services (911/equivalent) must be contacted immediately if severe, life-threatening outcomes are observed. These documented severe manifestations include collapse, a seizure, significant trouble breathing, or the inability to be awakened. In all suspected overdose cases, the mandated action is to seek emergency medical attention and contact the poison control helpline.

For supportive management, regulatory information provides specific constraints. No specific antidote is formally documented for Flavoxate overdose, and the prescribing information notes that it is officially not known whether the substance is dialyzable. Furthermore, special consideration is given to patients with renal impairment, as official labeling indicates that this condition may significantly affect the clearance kinetics of the product.

Therapeutic Uses of Urol

Urol is considered relevant for managing symptoms related to involuntary muscle spasms and heightened irritation within the lower urinary tract. Its therapeutic relevance is aligned with easing the overall symptom burden in clinical domains where additional symptomatic support is needed. The medication may be part of symptomatic management for key urinary symptoms.


Relief from Disruptive Urgency and Frequency

This domain addresses symptoms that create noticeable physiological strain, including compelling urinary urgency, frequent daytime voiding, and nocturia (waking up at night to urinate). Urol may be applied in addressing symptoms that become more disruptive during flare-ups, and supports the patient during difficult episodes by easing distress. It is relevant in situations involving conditions characterized by periods of heightened symptoms, such as cystitis, urethritis, prostatitis, and urethrotrigonitis.

Easing Pain and Symptomatic Support

Urol may assist with easing symptoms related to physical discomfort, such as painful urination (dysuria), burning sensations, and suprapubic pain. This application offers symptomatic relief in acute episodes, often used during phases when symptoms become more noticeable, such as after urological procedures or in settings where concurrent antibiotic therapy is applied. Urol supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

Quick Fact: Relief for Key Urinary Symptoms
Primary Symptom Domain Symptoms linked to organ-specific functional stress
Core Patient Benefit Supports general well-being during symptomatic phases
Typical Use Context Acute episodes of irritation/inflammation

Regulatory References

  1. NIH DailyMed Prescribing Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Urol?

Eligibility for Urol (Flavoxate hydrochloride) is strictly defined by regulatory authorities based on age and specific pre-existing health conditions, detailed in official prescribing information.

Populations Approved and Contraindicated

Eligibility Status Defined Regulatory Status
Approved Use Adults and adolescents aged 12 years and older (safety and effectiveness established).
Use Not Recommended Children below 12 years (safety and effectiveness are not established).
Absolute Contraindication Patients with specific obstructive conditions of the gastrointestinal or urinary tracts.

Conditions That Prohibit Use

Urol is absolutely contraindicated in individuals diagnosed with any of the following severe conditions, as the medication must not be used:

  • Pyloric or duodenal obstruction
  • Obstructive intestinal lesions or ileus
  • Achalasia
  • Gastrointestinal hemorrhage
  • Obstructive uropathies of the lower urinary tract

Special Population Restrictions

Use in certain populations is conditional or requires caution as documented by regulators:

  • Pregnancy and Lactation: Use during pregnancy is classified as Category B and is only advised if clearly needed. For nursing mothers, caution is necessary as it is not known whether the drug passes into human milk.
  • Geriatric Patients: Older adults may require special monitoring due to a potentially increased incidence of mental confusion.
  • Other Conditions: The drug should be used with caution in patients with suspected glaucoma.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Flavoxate hydrochloride is defined primarily by its pharmacodynamic properties, as documented in governmental regulatory prescribing information. The official labeling does not specify any formal drug-drug contraindications or list interactions based on metabolic pathways like CYP enzymes or drug transporters. Furthermore, no mandated separation times are documented for the administration of co-administered medications.

The key interaction concern noted is the potential for additive pharmacodynamic effects. Co-administration with other medicinal products that cause central nervous system (CNS) depression carries a risk of reinforcing effects such as drowsiness and blurred vision. This caution also applies to the use of alcohol, which may intensify these CNS effects. The official labeling indicates that Flavoxate hydrochloride is compatible with medicinal products utilized for the treatment of urinary tract infections.

A specific population-dependent interaction consideration is documented for elderly patients, who are noted to have a heightened susceptibility to CNS adverse reactions, particularly mental confusion.

Interaction Classification Regulatory Finding
Pharmacodynamic Effect Additive CNS effects (drowsiness, blurred vision)
Metabolic/PK Interactions None explicitly documented
Population-Specific Note Increased risk of mental confusion in elderly patients
Formal Contraindications None explicitly documented (Drug-Drug)

Mechanism of Action

Urol acts as a selective competitive inhibitor to modulate the cyclic Guanosine Monophosphate ( cGMP) signaling pathway. Its mechanism relies on the localized amplification of an endogenous signal at the cellular level.

Modulating the cGMP Signaling Cascade

The drug's primary action is the inhibition of the Phosphodiesterase type 5 ( PDE5) enzyme. This enzyme is responsible for the degradation of the signaling molecule cGMP. By blocking PDE5, Urol prevents the breakdown of cGMP, leading to an increase in its intracellular concentration. The elevated cGMP levels initiate a cascade that promotes the relaxation of vascular smooth muscle cells, causing localized changes in vascular function.

Amplifying Endogenous Vasodilation

By preserving cGMP, Urol potentiates the naturally occurring Nitric Oxide ( NO) signal that initiates muscle relaxation. This action is predominantly peripheral, leading directly to a reduction in vascular resistance in targeted capillary beds. This selective, localized increase in blood flow volume is the core physiological effect resulting from PDE5 inhibition.

Dosage and Administration Information

Urol (Flavoxate hydrochloride) is administered via the oral route using a tablet formulation. Available strengths include 100 mg and 200 mg tablets, depending on the region.


Standard Dosing and Frequency

The medicine is used according to a structured regimen for symptomatic support. The typical dose prescribed ranges from 100 mg to 200 mg taken during each administration. This quantity is usually repeated three or four times daily, which places the total daily dose for an adult in the range of 300 mg to 800 mg. A core principle of the regimen is to reduce the dosage once symptoms begin to show improvement.


Administration Conditions and Constraints

Urol tablets are taken whole and do not require dilution or special preparation. Regarding intake relative to meals, the medication may be taken with or without food, though taking the tablet after a meal may help prevent potential gastrointestinal upset. If a dose is missed, instructions advise against taking a double dose. Instead, the missed dose should be skipped if the next scheduled administration is near.


Population-Specific Rules

The instructions establish an age-based constraint on usage. The safety and effectiveness of Flavoxate hydrochloride have not been established for patients under 12 years of age, and therefore, use in this pediatric group is not recommended.

Recent Clinical Evidence

Research evidence / Overview of Studies for Urol (Flavoxate)

Overview of the Clinical Study Landscape

Research into Urol, which contains flavoxate, is supported by a research base that includes randomized controlled trials (RCTs). These studies were used to examine patterns of change in patient-reported symptoms and functional measures. The available evidence contributes to the broader evidence landscape by describing symptom patterns measured during the study periods. Much of the available evidence is drawn from older studies, and scientific reviews describe the methodological quality and scale of this research when summarizing the overall evidence landscape.


Evidence for Symptomatic Relief in Lower Urinary Tract Irritation

Research was studied for use in patients experiencing symptoms such as urgency, frequency, and painful urination (dysuria) associated with conditions like cystitis, urethritis, and prostatitis. These research scenarios focused on episodes where symptoms become more noticeable and create noticeable physiological strain. Short-term clinical trials and RCTs were the primary study designs used, examining outcomes related to physical discomfort and frequency patterns. Research describes patterns observed during the study period in outcomes related to these irritative states, helping contextualize the short-term changes in patient-reported experiences of discomfort. Follow-up durations were often limited, contributing to limited information for long-term outcomes.


Research Findings Related to Overactive Bladder (OAB) Symptoms

Urol was evaluated in studies exploring outcomes related to symptoms where intensity may vary, often seen in OAB. Urodynamic studies described the research context used to measure bladder muscle activity and bladder capacity. Findings related to changes in micturition frequency were reported, and some studies described patterns related to changes in bladder capacity measurements. Official reviews often note that comparative evidence against other pharmacological agents is lacking, and the evidence quality varies across studies, indicating that certainty remains low.


What is Still Uncertain About Urol Research

The research provides context but not individual predictions regarding symptom change. Limitations discussed in scientific literature include the age and generally modest sample sizes of many foundational randomized controlled trials. There is limited information for long-term outcomes and the durability of any observed changes beyond short study durations. Comparative evidence is lacking against many pharmacological agents, meaning that comparative certainty remains low.

Key Studies & References

  1. Flavoxate Hydrochloride Tablets 100 mg, Film-Coated Prescribing Information - DailyMed
  2. Flavoxate in the symptomatic treatment of overactive bladder: a meta-analysis
  3. Flavoxate: present and future (Review focusing on Urodynamics and OAB)

Frequently Asked Questions (FAQ)

Common questions about Urol (FAQ)


Q: How quickly should I expect Urol to start working?

Official product information, citing clinical studies, describes the observed speed of action. In a study of male subjects, the onset of action—the time the medicine began to counteract smooth muscle spasm—was observed to occur at approximately 55 minutes.


Q: What does 'onset of action' mean for Urol?

For Urol, 'onset of action' is a term used in regulatory documents to describe the approximate time it took in clinical research for the medicine to begin its initial effect. The drug's action is described as the counteracting of smooth muscle spasm in the urinary tract, which is the mechanism intended to address discomfort.


Q: How long does Urol typically stay in your system?

Regulatory documents indicate that the active ingredient is processed by the body and primarily eliminated through the kidneys. In a single study, approximately 57% of the active ingredient was reported to be excreted in the urine within 24 hours.


Q: Can Urol be taken with common over-the-counter pain relievers?

Official labeling does not explicitly specify a formal drug-drug contraindication with common over-the-counter pain relievers. However, caution is advised when taking other medicines that may cause central nervous system (CNS) depression—effects like drowsiness or blurred vision—due to the potential for reinforced effects.


Q: Are there any foods or drinks I need to avoid while taking Urol?

Official information explicitly notes that the use of alcohol may intensify side effects such as drowsiness and blurred vision. Regulatory documents describe that the medicine may be taken with or without food, although some sources note that taking the tablet after a meal may help reduce the chance of stomach upset.


Q: What are the most common side effects of Urol that people report?

Officially documented adverse reactions classified as common in some regions include dry mouth, nausea, headache, drowsiness, and blurred vision. These observations are documented in the official safety profile according to affected body systems.


Q: Are there long-term side effects associated with Urol use?

The official product information notes that long-term studies in humans providing data on outcomes after many years of use have not been described. Additionally, official labeling does not contain available data from animal studies examining the long-term potential for cancer-causing effects.


Q: Does Urol interact with birth control pills?

The regulatory documents defining the drug's interaction profile do not explicitly specify a formal drug-drug contraindication or list an interaction with hormonal contraceptives.


Q: What if I'm taking Urol and also drinking coffee or energy drinks?

Official labeling specifically cautions that products with additive central nervous system (CNS) effects, such as alcohol, may intensify side effects like drowsiness. The potential effect of other common stimulants on the medicine’s side effects is not directly addressed in the official regulatory labeling.


Q: Can Urol cause changes in mood or sleep?

Official documents list drowsiness (somnolence) as an observed side effect that can affect sleep. Nervousness is also listed as an adverse reaction. Furthermore, a potential for mental confusion is noted, particularly for older adults.


Q: What is the evidence regarding Urol's effectiveness?

Studies described in regulatory documents include randomized controlled trials that examined patterns of patient-reported symptoms. The available research evidence describes outcomes related to symptomatic changes in issues such as urgency, frequency, and painful urination associated with lower urinary tract irritation.


Q: Is Urol used for other conditions besides what my doctor told me?

Regulatory documents indicate that Flavoxate hydrochloride is intended for the symptomatic relief of certain urinary issues, such as painful or frequent urination. The label states the drug is not indicated for definitive treatment of underlying diseases, but it is compatible with drugs used for such treatment.


Q: Does Urol treat the symptoms or the underlying problem?

Regulatory documents indicate that Urol is specifically intended for symptomatic relief of lower urinary tract irritation. The official label notes that it is not indicated for definitive treatment of the underlying cause, but it is compatible with other drugs used to address underlying conditions like urinary tract infections.


Q: Is it normal to feel a bit tired when starting Urol?

Drowsiness (somnolence) is listed in the official safety profile as a central nervous system (CNS) adverse reaction that has been observed in patients using Urol. The occurrence of drowsiness is formally documented as an observed side effect.


Q: Is there a generic version of Urol available?

The active ingredient, Flavoxate hydrochloride, is associated with Abbreviated New Drug Applications (ANDA) documented in the official regulatory system.


Q: Is Urol habit-forming or addictive?

Official regulatory labeling includes a section on drug abuse and dependence. Flavoxate hydrochloride is not classified as a controlled substance by the DEA (Drug Enforcement Administration). This status indicates that the drug does not carry a formal classification related to addiction or abuse potential.


Q: Is Urol considered a common or specialized medication?

Urol, which contains the active ingredient Flavoxate, is officially classified as a Urinary Antispasmodic and a Urological Agent. The classification suggests its use is within the medical area of urology, which addresses issues of the urinary system.


Q: Is there a maximum time someone can safely take Urol?

While the regulatory documents do not specify a fixed maximum treatment duration, the official instructions indicate that the dose should be reduced once symptoms begin to show improvement.

How should Urol be stored and disposed of?

How to Store and Dispose of Flavoxate Hydrochloride (Urol)

Official regulatory documentation specifies precise conditions for the storage and disposal of Urol (Flavoxate hydrochloride) tablets.

Storage/Disposal Aspect Official Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F)
Container Keep in the original container, tightly closed
Child Safety Store out of the reach of children
Disposal Utilize a drug take-back program or follow household disposal instructions

The medication must be maintained within the specified temperature range; temporary excursions up to 30 C (86 F) are permitted. The container must remain tightly closed to preserve product integrity. For disposal, unused or expired tablets should not be flushed; instead, patients are directed to use established drug take-back sites or follow FDA guidelines for mixing with undesirable substances before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urol found in:

A-Z Index: